Stock listing

NASDAQ:BBOT BridgeBio Oncology Therapeutics, Inc. Stock

Home listing (NASDAQ) of BridgeBio Oncology Therapeutics, Inc.

Follow BridgeBio Oncology Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:BBOT

$1.81 USD +0.01 (+0.3%)

Close on Nov 20, 2026

Past year -85.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.79 – $1.94 USDNov 20, 2026
Volume
450,960 sharesNov 20, 2026
Market cap
$145.3M USDAt the close on Nov 20, 2026 · price × 80.25M shares outstanding
52-week range
$1.79 – $14.87 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.48M USDMedian day 505,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
BridgeBio Oncology Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:BBOT · Home$1.81 USD+0.005 (+0.3%)450,960$1.87$1.94$1.785$1.805Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BBOT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.81+0.005+0.3%$1.87$1.94$1.785450,960
$1.805-0.135-7.0%$1.91$1.96$1.79576,715
$1.94-0.04-2.0%$2.00$2.075$1.93374,899
$1.98-0.16-7.5%$2.13$2.226$1.97801,455
$2.14-0.21-8.9%$2.37$2.37$2.11677,478
$2.35-0.21-8.2%$2.50$2.68$2.00778,968
$2.56+0.36+16.4%$2.33$2.645$2.251,423,704
$2.20-0.10-4.3%$2.29$2.34$2.185486,662
$2.30+0.26+12.7%$2.09$2.34$2.07780,794
$2.04-0.13-6.0%$2.19$2.25$1.985686,343
$2.17-0.13-5.7%$2.30$2.30$2.075699,092
$2.30-0.02-0.9%$2.33$2.39$2.22451,527
$2.32+0.01+0.4%$2.30$2.40$2.29621,014
$2.31-0.31-11.8%$2.64$2.64$2.295579,578
$2.62-0.08-3.0%$2.70$2.74$2.605314,785
$2.70-0.10-3.6%$2.81$2.948$2.69357,036
$2.80+0.11+4.1%$2.67$2.855$2.61482,179
$2.69+0.05+1.9%$2.65$2.725$2.511,755,926
$2.64-0.02-0.8%$2.66$2.68$2.61483,080
$2.66-0.19-6.7%$2.83$2.83$2.60737,317
$2.85+0.17+6.3%$2.66$2.85$2.66661,895
$2.68-0.04-1.5%$2.71$2.855$2.66942,242
$2.72-0.13-4.6%$2.85$2.98$2.70660,932
$2.85+0.03+1.1%$2.84$2.90$2.79695,643
$2.82-0.13-4.4%$2.95$2.95$2.81480,800
$2.95+0.045+1.5%$2.90$3.304$2.86473,900
$2.905-0.045-1.5%$2.94$3.07$2.88440,600
$2.95-0.31-9.5%$3.24$3.34$2.93505,700
$3.26-0.05-1.5%$3.31$3.37$3.23234,000
$3.31-0.11-3.2%$3.43$3.50$3.295472,000
$3.42-0.02-0.6%$3.43$3.43$3.27566,200
$3.44-0.06-1.7%$3.46$3.57$3.36321,300
$3.50-0.10-2.8%$3.60$3.72$3.48659,700
$3.60-0.29-7.5%$3.88$3.88$3.575481,600
$3.89-0.05-1.3%$3.97$4.045$3.88486,000
$3.94-0.16-3.9%$4.05$4.10$3.821,363,700
$4.10+0.18+4.6%$3.94$4.15$3.875736,300
$3.92+0.11+2.9%$3.83$4.02$3.80537,400
$3.81-0.14-3.5%$3.91$3.925$3.79476,600
$3.95-0.04-1.0%$4.00$4.00$3.89523,500
$3.99-0.17-4.1%$4.15$4.17$3.90656,600
$4.16-0.50-10.7%$4.61$4.70$4.05539,600
$4.660.000.0%$4.63$4.81$4.60509,100
$4.66-0.11-2.3%$4.84$4.84$4.594468,700
$4.77-0.12-2.5%$4.86$4.86$4.691,229,800
$4.89+0.13+2.7%$4.84$5.10$4.84415,400
$4.76-0.12-2.5%$4.93$4.99$4.71855,300
$4.88-0.17-3.4%$5.01$5.015$4.72629,200
$5.05+0.10+2.0%$4.91$5.18$4.85956,000
$4.95-0.57-10.3%$5.53$5.616$4.901,630,900
$5.52-1.235-18.3%$6.785$6.785$5.482,789,400
$6.755-2.105-23.8%$8.86$8.86$6.2951,498,900
$8.86-0.12-1.3%$8.88$9.05$8.775152,500
$8.98+0.08+0.9%$8.80$9.06$8.65117,600
$8.90+0.01+0.1%$8.93$9.041$8.66139,200
$8.89+0.07+0.8%$8.81$9.185$8.73238,900
$8.82+0.02+0.2%$8.70$8.90$8.535145,600
$8.80+0.06+0.7%$8.72$9.195$8.41476,000
$8.74-0.44-4.8%$9.16$9.16$8.69195,000
$9.18-0.08-0.9%$9.19$9.315$9.06385,300
$9.26-0.11-1.2%$9.36$9.47$9.04247,200
$9.37+0.23+2.5%$9.24$9.473$9.18197,974
$9.14+0.06+0.7%$9.10$9.358$8.80338,518
$9.080.000.0%$9.19$9.435$9.03170,900
$9.08-0.52-5.4%$9.55$9.78$9.08203,300
Ticker
NASDAQ:BBOT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All BridgeBio Oncology Therapeutics, Inc. news

BridgeBio Oncology Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
17 in the last 12 months · 27 in all · newest Nov 10, 2026 · oldest 2025
Decks
5 decks · latest September 2026

Where BridgeBio Oncology Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:BBOT · Home listing · This pageNASDAQUnited StatesUSD
BOATS:BBOTBOATSUnited StatesUSD
BIVA:BBOTBIVAMexicoMXN
BMV:BBOTBMVMexicoMXN

Valuation

Price/book 0.5× against a median of 1.7×: 2nd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$46.23M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.49

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
BridgeBio Oncology Therapeutics, Inc. · NASDAQ:BBOTUS$145.3M−US$46.23Mn/an/an/a0.5×n/a0.0×1.49
Eledon Pharmaceuticals, Inc. · NASDAQ:ELDNUS$150.3MUS$80.67Mn/an/an/a4.9×n/a0.0×1.95
Veraxa Biotech AG · NASDAQ:VRXAUS$147.1MUS$145.1Mn/a5,202×n/an/an/an/a1.11
ProQR Therapeutics N.V. · NASDAQ:PRQRUS$146.8MUS$49.73Mn/a2.2×n/a2.0×−210.7%0.2×1.73
ALX Oncology Holdings Inc. · NASDAQ:ALXOUS$146.6MUS$9.57Mn/an/an/a1.2×n/a0.1×0.68
Bicycle Therapeutics PLC · NASDAQ:BCYCUS$146.1M−US$323.8Mn/a−3.9×n/a0.3×−169.8%0.0×1.59
TYK Medicines, Inc. Class H · HKEX:2410US$144.9MUS$137.1Mn/an/an/a3.7×n/a0.6×n/a
Sutro Biopharma, Inc. · NASDAQ:STROUS$142.8MUS$259.6Mn/a5.8×n/an/a−344.2%n/a1.14
VISEN Pharmaceuticals · HKEX:2561US$140.7MUS$91.39Mn/a29.9×n/a1.4×n/a0.3×n/a
Protara Therapeutics, Inc. · NASDAQ:TARAUS$140.4MUS$15.77Mn/an/an/a1.0×n/a0.0×1.12
Cloudbreak Pharma, Inc. · HKEX:2592US$140.4MUS$82.02Mn/an/an/a2.3×n/a0.0×n/a
Median of the othersUS$145.5MUS$81.35M5.8×1.7×−210.7%0.1×1.14

Forecasts

8 strong buy · 4 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
23.00 USD · Analysts' mean
EPS, year to Dec 2026
-1.93 · 3 analysts

Team and board

Officers

OfficerRole
Pedro J. BeltranChief Executive Officer
Uneek MehraChief Financial Officer
Idan ElmelechChief Operating Officer
Heather ArmstrongHead of Investor Relations BBOT
Aaron ChanVice President, Legal
Bin WangSenior Vice President, Drug Discovery
Chunmei JiVice President, Head of Toxicology
Daniel WatsonSenior Vice President, Chemistry, Manufacturing, and Controls
Foster GonsalvesVice President, Early Development
Hua GongVice President, Translational Medicine
Joon Whan RheeVice President, Clinical Development
Kerstin SinkeviciusVice President, Pharmacology
Marc CoboVice President of Finance and Controller
Rui XuSenior Vice President, Drug Discovery
Sunyoung LeeVice President, Regulatory Affairs
Frank McCormickCofounder, Non-Executive Director
Neil KumarExecutive Chairman
Yong BenChief Medical and Development Officer

Board

DirectorRole
Jake BauerChairman
Neil KumarExecutive Chairman
Bihua ChenDirector
Frank McCormickCofounder, Non-Executive Director
Peter F. LebowitzDirector
Praveen TipirneniNon-Executive Director
Raymond KelleherDirector

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · After close+16.4%
Q2 2026Aug 11, 2026 · After close+2.4%
Q1 2026May 13, 2026+4.7%
Q4 2025Mar 5, 2026 · After close+5.4%
Q3 2025Nov 12, 2025 · After close−2.0%
Q2 2025Sep 3, 2025+5.2%
Q1 2025May 28, 2025
Q4 2024Mar 11, 2025

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck35 slidesSeptember 2026
SPAC Merger (February 2025)SPAC merger50 slidesFeb 28, 2025
ENA 2024Conference19 slides2024
Technical Presentation (September 2023)Technical30 slidesSeptember 2023
5th Annual RAS-Targeted Drug Development Summit (September 2023)Conference28 slidesSeptember 2023

Open Decks

IPO

Went public as Helix Acquisition Corp. II, a blank check company (SPAC). Priced at US$10.00 a share on Feb 8, 2024.

Price
US$10.00 a share
Shares offered
16,000,000 Class A ordinary shares
Offering size
US$160 million
Underwriters' option
Up to 2,400,000 more shares
Listing
HLXB on the Nasdaq Global Market
Underwriter
Leerink Partners
Shares delivered
On or about Feb 13, 2024

Steps

StepWhen
Draft sent to the SEC in confidenceDec 20, 2023
Filed publiclyJan 18, 2024
Amended twiceNewest Feb 7, 2024
Shares registered with an exchangeFeb 8, 2024
Declared effective by the SECFeb 8, 2024
Final prospectus, with the priceFeb 13, 2024

Open IPO · From the cover of the final prospectus (424B4) filed Feb 13, 2024

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021
Revenue000
Cost of revenue610.0K
Gross profit-610.0K
Research and development121.2M73.1M56.3M
Selling, general and administrative24.6M7.76M8.48M3.52K74.3K
Operating income-145.8M-80.9M-41.7K-3.52K-43.4K
Depreciation and amortization280.0K208.0K92.0K3.52K74.3K
EBITDA-145.5M-80.7M50.3K031.0K
Income before tax-134.0M-74.3M-64.7M-3.52K-43.4K
Income tax00
Net income-134.0M-74.3M-41.7K-3.52K-43.4K
Earnings per share, basic-4.30-5,756.41-0.00-0.00-0.00
Earnings per share, diluted-4.30-5,756.41

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021
Cash and equivalents373.7M30.9M0
Short-term investments51.8M124.8M0
Receivables386.0K
Current assets432.4M158.7M3.94M
Property, plant and equipment956.0K490.0K
Total assets448.4M164.3M332.9K144.6K144.3K
Accounts payable1.37M3.07M575.0K
Current liabilities35.0M19.6M396.5K166.5K162.6K
Total debt2.77M70.1K43.1K37.0K
Total liabilities37.3M19.6M396.5K166.5K162.6K
Shareholders' equity411.1M-178.6M-115.6M-21.9K-18.4K
Shares outstanding80.0M28.4K80.0M20.5M20.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021
Cash from operations-113.9M-55.0M-52.1M
Capital spending-606.0K-49.0K-414.0K00
Free cash flow-114.5M-55.1M-52.5M
Cash from investing73.3M-120.5M-2.82M
Cash from financing383.4M206.3M55.1M
Change in cash342.8M30.7M225.0K

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 20, 2026Insider tradeSEC
144 · Notice of proposed saleNov 18, 2026Other filingsSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
144 · Notice of proposed saleNov 13, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
8-K · Current reportNov 5, 2026Management or board changeSEC
4 · Change in ownershipOct 23, 2026Insider tradeSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
All 192 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 5, 2026Insider tradeSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveSep 11, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveSep 9, 2026Other filingsSEC
8-K · Current reportSep 8, 2026Current reportSEC
S-3 · Registration statementSep 1, 2026Offer documentSEC
POS AM · Amendment to an effective registrationSep 1, 2026Offer documentSEC
424B3 · ProspectusAug 11, 2026Offer documentSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 6, 2026Big-stake noticeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
424B3 · ProspectusJun 22, 2026Offer documentSEC
8-K · Current reportJun 22, 2026Management or board changeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
424B3 · ProspectusMay 13, 2026Offer documentSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
4 · Change in ownershipMay 12, 2026Insider tradeSEC
4 · Change in ownershipMay 12, 2026Insider tradeSEC
424B3 · ProspectusMay 6, 2026Offer documentSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveMay 5, 2026Other filingsSEC
POS AM · Amendment to an effective registrationApr 30, 2026Offer documentSEC
3 · Initial statement of ownershipApr 30, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 30, 2026Insider tradeSEC
424B3 · ProspectusApr 29, 2026Offer documentSEC
8-K · Current reportApr 29, 2026Management or board changeSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
424B3 · ProspectusApr 22, 2026Offer documentSEC
8-K · Current reportApr 22, 2026Management or board changeSEC
4 · Change in ownershipMar 26, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 26, 2026Insider tradeSEC
424B3 · ProspectusMar 26, 2026Offer documentSEC
8-K · Current reportMar 26, 2026Management or board changeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
424B3 · ProspectusMar 6, 2026Offer documentSEC
10-K · Annual reportMar 5, 2026Annual reportSEC
8-K · Current reportMar 5, 2026ResultsSEC
424B3 · ProspectusJan 7, 2026Offer documentSEC
424B3 · ProspectusJan 7, 2026Offer documentSEC
8-K · Current reportJan 7, 2026Current reportSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJan 2, 2026Offer documentSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
4 · Change in ownershipOct 16, 2025Insider tradeSEC
S-8 · Registration statement for employee plansOct 10, 2025Offer documentSEC
4 · Change in ownershipOct 6, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveSep 11, 2025Other filingsSEC
424B3 · ProspectusSep 10, 2025Offer documentSEC
CORRESP · Letter to the SECSep 8, 2025Other filingsSEC
UPLOAD · Letter from the SECSep 3, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeSep 3, 2025Big-stake noticeSEC
S-1 · Registration statementAug 29, 2025Offer documentSEC
4 · Change in ownershipAug 28, 2025Insider tradeSEC
4 · Change in ownershipAug 28, 2025Insider tradeSEC
4 · Change in ownershipAug 28, 2025Insider tradeSEC
4 · Change in ownershipAug 28, 2025Insider tradeSEC
4 · Change in ownershipAug 28, 2025Insider tradeSEC
4 · Change in ownershipAug 28, 2025Insider tradeSEC
4 · Change in ownershipAug 28, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveAug 20, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeAug 18, 2025Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeAug 18, 2025Big-stake noticeSEC
3 · Initial statement of ownershipAug 18, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 18, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 18, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 18, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 18, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 18, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 18, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 18, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 18, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 18, 2025Insider tradeSEC
POS AM · Amendment to an effective registrationAug 14, 2025Offer documentSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
8-K · Current reportAug 12, 2025Acquisition or disposalSEC
3 · Initial statement of ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
8-K · Current reportAug 6, 2025Current reportSEC
425Aug 4, 2025Other filingsSEC
8-K · Current reportAug 4, 2025Meeting outcomeSEC
10-Q · Quarterly reportAug 1, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 30, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 24, 2025Big-stake noticeSEC
424B3 · ProspectusJul 21, 2025Offer documentSEC
425Jul 21, 2025Other filingsSEC
425Jul 11, 2025Other filingsSEC
8-K · Current reportJul 11, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveJul 11, 2025Other filingsSEC
424B4 · ProspectusJul 10, 2025Offer documentSEC
CORRESP · Letter to the SECJul 9, 2025Other filingsSEC
S-4/A · Registration statement, amendedJul 9, 2025Offer documentSEC
CORRESP · Letter to the SECJul 1, 2025Other filingsSEC
S-4/A · Registration statement, amendedJul 1, 2025Offer documentSEC
UPLOAD · Letter from the SECJun 27, 2025Other filingsSEC
CORRESP · Letter to the SECJun 20, 2025Other filingsSEC
S-4 · Registration statementJun 20, 2025Offer documentSEC
UPLOAD · Letter from the SECJun 11, 2025Other filingsSEC
DRSLTR · Letter to the SEC with a draftMay 30, 2025Other filingsSEC
DRS/A · Draft registration statement, amendedMay 30, 2025Offer documentSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
UPLOAD · Letter from the SECMay 13, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 22, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 15, 2025Big-stake noticeSEC
DRSLTR · Letter to the SEC with a draftApr 14, 2025Other filingsSEC
DRS · Draft registration statementApr 14, 2025Offer documentSEC
10-K · Annual reportMar 10, 2025Annual reportSEC
425Mar 6, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 4, 2025Big-stake noticeSEC
425Feb 28, 2025Other filingsSEC
8-K · Current reportFeb 28, 2025Material contractSEC
425Feb 28, 2025Other filingsSEC
8-K · Current reportFeb 28, 2025Current reportSEC
3 · Initial statement of ownershipFeb 11, 2025Insider tradeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
8-K · Current reportFeb 10, 2025Management or board changeSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 22, 2024Big-stake noticeSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
SC 13G · Big-stake noticeFeb 23, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 23, 2024Big-stake noticeSEC
SC 13D · Big-stake noticeFeb 20, 2024Big-stake noticeSEC
8-K · Current reportFeb 20, 2024Current reportSEC
SC 13G · Big-stake noticeFeb 15, 2024Big-stake noticeSEC
8-K · Current reportFeb 14, 2024Material contractSEC
4 · Change in ownershipFeb 13, 2024Insider tradeSEC
4 · Change in ownershipFeb 13, 2024Insider tradeSEC
424B4 · ProspectusFeb 12, 2024Offer documentSEC
3 · Initial statement of ownershipFeb 9, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 9, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 9, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveFeb 9, 2024Other filingsSEC
S-1MEF · Registration of more shares for the same offeringFeb 8, 2024Offer documentSEC
3 · Initial statement of ownershipFeb 8, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 8, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 8, 2024Insider tradeSEC
CERT · Exchange's certificate of listingFeb 8, 2024Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeFeb 8, 2024Other filingsSEC
CORRESP · Letter to the SECFeb 7, 2024Other filingsSEC
CORRESP · Letter to the SECFeb 7, 2024Other filingsSEC
CORRESP · Letter to the SECFeb 6, 2024Other filingsSEC
S-1/A · Registration statement, amendedFeb 6, 2024Offer documentSEC
UPLOAD · Letter from the SECFeb 6, 2024Other filingsSEC
CORRESP · Letter to the SECFeb 2, 2024Other filingsSEC
S-1/A · Registration statement, amendedFeb 2, 2024Offer documentSEC
UPLOAD · Letter from the SECJan 23, 2024Other filingsSEC
CORRESP · Letter to the SECJan 18, 2024Other filingsSEC
S-1 · Registration statementJan 18, 2024Offer documentSEC
UPLOAD · Letter from the SECJan 10, 2024Other filingsSEC
DRS · Draft registration statementDec 20, 2023Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from BridgeBio Oncology Therapeutics, Inc.’s releases · as of Nov 5, 2026

Common shares
80,251,267
Fully diluted
80,251,267

Fully diluted

LineSharesAs of
Common shares80,251,267Nov 5, 2026

Share count over time

CountShares
Nov 5, 202680,251,267

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Cormorant Asset Management, LP17.9M22.3%US$73.3MSep 30, 2026
BlackRock4.01M5.0%US$16.4MSep 30, 2026
Omega Fund Management, LLC3.29M4.1%US$13.5MSep 30, 2026
Deerfield Management Company, L.P.3.14M3.9%US$12.9MSep 30, 2026
Alphabet Inc.2.82M3.5%US$11.6MSep 30, 2026
Citadel2.7M3.4%US$11.1MSep 30, 2026
Enavate Sciences Gp, LLC2.63M3.3%US$10.8MSep 30, 2026
Regents Of The University Of California2.51M3.1%US$10.3MSep 30, 2026
Vanguard2.27M2.8%US$9.32MSep 30, 2026
Armistice Capital, LLC2.26M2.8%US$9.28MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Novo Holdings A/S2.25M2.8%US$9.22MSep 30, 2026
Laurion Capital Management LP2M2.5%US$8.21MSep 30, 2026
Wellington1.43M1.8%US$5.87MSep 30, 2026
Aisling Capital Management LP1.02M1.3%US$4.14MSep 30, 2026
State Street893K1.1%US$3.66MSep 30, 2026
EcoR1 Capital, LLC890K1.1%US$3.65MSep 30, 2026
Catalio Capital Management, LP700K0.87%US$2.87MSep 30, 2026
Opaleye Management Inc.630K0.79%US$2.58MSep 30, 2026
Geode Capital557K0.69%US$2.28MSep 30, 2026
Marshall Wace, LLP483K0.60%US$1.98MSep 30, 2026
Sphera Funds Management LTD.464K0.58%US$1.9MSep 30, 2026
Granahan Investment Management, LLC437K0.54%US$1.79MSep 30, 2026
Adage Capital Partners Gp, L.L.C.400K0.50%US$1.64MSep 30, 2026
BNP Paribas350K0.44%US$1.43MSep 30, 2026
T. Rowe Price299K0.37%US$1.23MSep 30, 2026
Qube Research & Technologies Ltd291K0.36%US$1.19MSep 30, 2026
Schwab286K0.36%US$1.17MSep 30, 2026
Casdin Capital, LLC282K0.35%US$1.16MSep 30, 2026
DAFNA Capital Management LLC266K0.33%US$1.09MSep 30, 2026
Goldman Sachs240K0.30%US$982KSep 30, 2026
Ensign Peak Advisors, Inc229K0.28%US$937KSep 30, 2026
Brevan Howard Capital Management LP165K0.21%US$677KSep 30, 2026
Squarepoint Ops LLC157K0.20%US$644KSep 30, 2026
Millennium144K0.18%US$592KSep 30, 2026
Victory Capital129K0.16%US$527KSep 30, 2026
Moore Capital Management, LP100K0.12%US$410KSep 30, 2026
Tema ETFS LLC99,7500.12%US$409KSep 30, 2026
Tidal Investments LLC99,7500.12%US$409KSep 30, 2026
Palumbo Wealth Management LLC95,4430.12%US$391KSep 30, 2026
RBC82,4390.10%US$338KSep 30, 2026
Schonfeld Strategic Advisors LLC67,8610.08%US$278KSep 30, 2026
Renaissance Technologies64,0000.08%US$262KSep 30, 2026
ExodusPoint Capital Management, LP60,5970.08%US$248KSep 30, 2026
EntryPoint Capital, LLC54,7560.07%US$225KSep 30, 2026
Axq Capital, LP53,0010.07%US$217KSep 30, 2026
Dimensional52,4060.07%US$214KSep 30, 2026
Bank of America50,8160.06%US$208KSep 30, 2026
Fox Run Management, L.L.C.50,7780.06%US$208KSep 30, 2026
Susquehanna48,2300.06%US$198KSep 30, 2026
TD42,7300.05%US$168KSep 30, 2026

This page holds 50 of 87 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.42M1.8%US$10.8MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF813K1.0%US$6.2MJun 30, 2026
BlackRock Health Sciences Opportunities Portfolio674K0.84%US$6.04MMay 29, 2026
Vanguard Extended Market Index Fund540K0.67%US$4.11MJun 30, 2026
iShares Biotechnology ETF306K0.38%US$2.33MJun 30, 2026
Fidelity Extended Market Index Fund251K0.31%US$2.25MMay 31, 2026
Select Biotechnology Portfolio240K0.30%US$2.16MMay 31, 2026
Schwab U.S. Small-Cap ETF227K0.28%US$2.04MMay 31, 2026
T. Rowe Price Health Sciences Fund, Inc.223K0.28%US$1.7MJun 30, 2026
Victory Small Cap Stock Fund135K0.17%US$1.09MJul 31, 2026
All 40 holders
HolderSharesOf the companyValueAs of
Tema Oncology ETF93,3390.12%US$837KMay 31, 2026
Fidelity Total Market Index Fund90,3760.11%US$811KMay 31, 2026
Royce Micro-Cap Fund87,6170.11%US$668KJun 30, 2026
Fidelity Series Total Market Index Fund72,9320.09%US$654KMay 31, 2026
Fidelity Nasdaq Composite Index Fund49,4590.06%US$444KMay 31, 2026
Health Sciences Portfolio40,6630.05%US$310KJun 30, 2026
Virtus Biotech Clinical Trials Etf40,1070.05%US$324KJul 31, 2026
Royce Small-Cap Fund38,0530.05%US$290KJun 30, 2026
Schwab Total Stock Market Index Fund32,0000.04%US$259KJul 31, 2026
Royce Capital Fund - Micro-Cap Portfolio28,9760.04%US$221KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund28,7920.04%US$219KJun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares27,6340.03%US$224KJul 31, 2026
Schwab U.S. Broad Market ETF27,5000.03%US$247KMay 31, 2026
Fidelity ZERO Total Market Index Fund24,9410.03%US$202KJul 31, 2026
Acuitas US Microcap Fund24,3500.03%US$186KJun 30, 2026
Fidelity ZERO Extended Market Index Fund18,5290.02%US$150KJul 31, 2026
T. Rowe Price Health Sciences Portfolio15,7740.02%US$120KJun 30, 2026
Small Cap Core Fund15,5790.02%US$119KJun 30, 2026
Harbor Active Small Cap Growth ETF12,2740.02%US$99,297Jul 31, 2026
Biotechnology Ultrasector Profund7,754<0.01%US$62,730Jul 31, 2026
Fidelity Flex Small Cap Index Fund7,506<0.01%US$60,724Jul 31, 2026
Health Sciences Trust7,262<0.01%US$55,336Jun 30, 2026
EQ/T.Rowe Price Health Sciences Portfolio4,884<0.01%US$37,216Jun 30, 2026
Vanguard Balanced Index Fund4,825<0.01%US$36,767Jun 30, 2026
VIP Extended Market Index Portfolio4,161<0.01%US$31,707Jun 30, 2026
Profund Vp Biotechnology3,606<0.01%US$27,478Jun 30, 2026
Goldman Sachs Absolute Return Tracker Fund3,155<0.01%US$24,041Jun 30, 2026
Total Stock Market Index Trust1,414<0.01%US$10,775Jun 30, 2026
VIP Total Market Index Portfolio1,180<0.01%US$8,992Jun 30, 2026
Pacer WealthShield ETF378<0.01%US$3,058Jul 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Beltran Pedro
Director, Officer: President and CEO
Sale1,870USD 1.84US$3,443Nov 18, 2026
Cobo Marc
Officer: Principal Accounting Officer
Sale78USD 2.37US$185Nov 13, 2026

Big stakes

StakeStakeSharesDateFiling
Bihua Chen22.32%17.9MJul 1, 2026Schedule 13D
BridgeBio Pharma LLC17.50%13.9MAug 11, 2025Schedule 13D
BC Global Opportunities IX LP5.50%4.37MSep 4, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
John Schmid
Other companies: BlossomHill Therapeutics, Inc. (Director · Since at least Aug 6, 2026); First Tracks Biotherapeutics, Inc. (Director · Since at least Apr 1, 2026); Helix Acquisition Corp. III (Director · Since at least Jan 22, 2026); Design Therapeutics, Inc. (Director · Since at least Mar 25, 2021); AnaptysBio, Inc. (Director · Since at least Feb 2, 2018); Xeris Biopharma Holdings, Inc. (Director · Oct 5, 2021 – Aug 12, 2024 · Past); MoonLake Immunotherapeutics (Director · Oct 19, 2020 – Oct 19, 2020 · Past); Poseida Therapeutics Inc (Director · Jul 9, 2020 – Jan 8, 2025 · Past); Neos Therapeutics Inc (Director · Jul 2, 2018 – Mar 19, 2021 · Past)
Director · Feb 8, 2024 – Feb 8, 2024 · Past
Mark McKenna
Other companies: Helix Acquisition Corp. III (Director · Since at least Jan 22, 2026); NewAmsterdam Pharma Company N.V. (Director · Since at least Jul 16, 2024); Spyre Therapeutics, Inc. (Board Member · Since at least Feb 1, 2024); Apogee Therapeutics, Inc. (Director · Since at least Aug 17, 2023); Freenome, Inc. (Director · Jun 11, 2024 – Jun 11, 2024 · Past); Prometheus Biosciences Inc (Chairman, President and CEO, Director · Mar 11, 2021 – Jun 16, 2023 · Past); Bausch Health Companies Inc. (President, Salix · Aug 2, 2018 – Aug 19, 2019 · Past)
Director · Feb 8, 2024 – Feb 8, 2024 · Past
Bihua Chen
Other companies: BlossomHill Therapeutics, Inc. (Director · Since at least Aug 6, 2026); Helix Acquisition Corp. III (Chairperson and CEO, Director · Since at least Jan 22, 2026); Biomea Fusion, Inc. (Director · Since at least Jun 11, 2025)
Director · Since at least Aug 11, 2025
Jake Bauer
Other companies: Immunovant, Inc. (Director · Since at least Apr 18, 2025); Enliven Therapeutics, Inc. (Chairman of the Board of Directors · Since at least Feb 23, 2023)
Director · Since at least Aug 11, 2025
Neil Kumar
Other companies: Maze Therapeutics, Inc. (Director · Since at least Mar 27, 2026); BridgeBio Pharma, Inc. (Chief Executive Officer, Director · Since at least Nov 16, 2023)
Executive Chairman · Since at least Aug 11, 2025
Jake Bauer
Other companies: Immunovant, Inc. (Board Member · Since at least Apr 9, 2026)
Chairman · Since at least Aug 11, 2025
Marc Cobo
Other companies: Tricida Inc (SVP, Finance & CAO · Jun 29, 2020 – Sep 10, 2020 · Past)
Vice President of Finance and Controller · Since at least Apr 21, 2026
Nebojsa Obradovic
Other companies: Helix Acquisition Corp. III (Chief Legal Officer · Since at least Jan 22, 2026)
Chief Legal Officer · Since at least Feb 8, 2024
Pedro J. Beltran
Other companies: BridgeBio Pharma, Inc. (Chief Executive Officer, Idan Elmelech as Chief Operating Officer · Since at least Apr 22, 2026)
Chief Executive Officer · Since at least Aug 11, 2025
Aaron ChanVice President, Legal · Since at least Nov 4, 2026
All 29 people
PersonSeat
Albert A Holman IIIDirector · Feb 8, 2025 – Feb 8, 2025 · Past
Bin WangSenior Vice President, Drug Discovery · Since at least Nov 4, 2026
Chunmei JiVice President, Head of Toxicology · Since at least Nov 4, 2026
Daniel WatsonSenior Vice President, Chemistry, Manufacturing, and Controls · Since at least Nov 4, 2026
Eli M WallaceChief Executive Officer, Director · Since at least Aug 11, 2025
Foster GonsalvesVice President, Early Development · Since at least Nov 4, 2026
Frank McCormickCofounder, Non-Executive Director · Since at least Mar 6, 2026
Heather ArmstrongHead of Investor Relations BBOT · Since at least May 12, 2026
Hua GongVice President, Translational Medicine · Since at least Nov 4, 2026
Idan ElmelechChief Operating Officer · Since at least Feb 28, 2025
Joon Whan RheeVice President, Clinical Development · Since at least Nov 4, 2026
Kerstin SinkeviciusVice President, Pharmacology · Since at least Oct 13, 2025
Peter F. LebowitzDirector · Since at least Nov 4, 2026
Praveen TipirneniNon-Executive Director · Since at least Aug 11, 2025
Raymond KelleherDirector · Since at least Aug 11, 2025
Rui XuSenior Vice President, Drug Discovery · Since at least Nov 4, 2026
Sunyoung LeeVice President, Regulatory Affairs · Since at least Nov 4, 2026
Uneek MehraChief Financial Officer · Since at least Nov 12, 2025
Yong BenChief Medical and Development Officer · Since at least Sep 8, 2026

Open People

Log in to ask 6ix AI your own questions about BridgeBio Oncology Therapeutics, Inc.